Current guidance
11 items
Each item compared with the same item in the previous release (Jul 17, 2026). Values in quotation marks are the company’s words.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Consolidated adjusted EBITDA | for Q2 FY2027 | — | “low- to mid-single-digit range” | Filing ↗ |
| New | Consolidated sales | for Q2 FY2027 | — | “low- to mid-single-digit range” | Filing ↗ |
| New | Consumer Group sales | for Q2 FY2027 | — | “low- to mid-single-digit range” | Filing ↗ |
| New | CPG sales | for Q2 FY2027 | — | “low-single-digit range” | Filing ↗ |
| New | PCG sales | for Q2 FY2027 | — | “mid- to high-single-digit range” | Filing ↗ |
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Adjusted EBITDA | “increase 5% to 10%” | for FY2027 | Company-defined | Jul 17, 2026 | 1 | Filing ↗ |
| Consolidated adjusted EBITDA | “low- to mid-single-digit range” | for Q2 FY2027 | Company-defined | Oct 6, 2026 | 1 | Filing ↗ |
| Consolidated adjusted EBITDA | “increase 5% to 10% compared to prior-year record results” | for FY2027 | Company-defined | Jul 17, 2026 | 1 | Filing ↗ |
| Consolidated sales | “low- to mid-single-digit range” | for Q2 FY2027 | Company-defined | Oct 6, 2026 | 1 | Filing ↗ |
| Consolidated sales | “increase 3% to 7% compared to prior-year record results” | for FY2027 | Company-defined | Jul 17, 2026 | 1 | Filing ↗ |
| Consumer Group sales | “low- to mid-single-digit range” | for Q2 FY2027 | Company-defined | Oct 6, 2026 | 1 | Filing ↗ |
| CPG sales | “low-single-digit range” | for Q2 FY2027 | Company-defined | Oct 6, 2026 | 1 | Filing ↗ |
| Incremental benefits | “$75 million” | for FY2027 | Company-defined | Jan 8, 2026 | 1 | Filing ↗ |
| PCG sales | “mid- to high-single-digit range” | for Q2 FY2027 | Company-defined | Oct 6, 2026 | 1 | Filing ↗ |
| Sales | “increase 3% to 7%” | for FY2027 | Company-defined | Jul 17, 2026 | 1 | Filing ↗ |
| SG&A optimization action incremental benefits | “an incremental $75 million” | for FY2027 | Company-defined | Jan 8, 2026 | 1 | Filing ↗ |
12 companies in Specialty chemicals. What they guide on, and who reported this season.
| RPM International | Oct 6, 2026 | 5 changes |
| Albemarle | Aug 5, 2026 | 24 changes |
| DuPont | Aug 4, 2026 | 11 changes |
| Cabot Corporation | Aug 3, 2026 | 4 changes |
| Eastman Chemical | Jul 30, 2026 | 9 changes |
| Huntsman | Jul 30, 2026 | 1 change |
| FMC Corporation | Jul 29, 2026 | 34 changes |
| Ashland | Jul 28, 2026 | 4 changes |
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2027 | FY2026 | FY2025 | No period |
|---|---|---|---|---|
| Adjusted EBITDA | 1 statement | — | — | — |
| Consolidated adjusted EBITDA | 3 statements | — | — | — |
| Sales and adjusted EBITDA growth | 1 statement | — | — | — |
| Adjusted EBIT | — | 3 statements | 2 statements | — |
| Benefits expected to be realized | — | 1 statement | — | — |
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Oct 6, 2026 | FY2027 Q1 | 0001193125-26-414916 | 5 | Open filing ↗ |
| Jul 17, 2026 | FY2026 Q4 | 0001193125-26-311276 | 12 | Open filing ↗ |
| Apr 8, 2026 | FY2026 Q3 | 0001193125-26-146312 | 0 | Open filing ↗ |
| Jan 8, 2026 | FY2026 Q2 | 0001193125-26-006976 | 13 | Open filing ↗ |
| Oct 1, 2025 | FY2026 Q1 | 0001193125-25-225841 | 8 | Open filing ↗ |
| Jul 24, 2025 | FY2025 Q4 | 0001193125-25-163802 | 7 | Open filing ↗ |
| Apr 8, 2025 | FY2025 Q3 | 0001193125-25-075093 | 6 | Open filing ↗ |
| Jan 7, 2025 | FY2025 Q2 | 0001193125-25-002536 | 10 | Open filing ↗ |